## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-028				
Estimated average	hurden				

0.5

hours per response..

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person* KAPLAN GILLA				2. Issuer Name and Ticker or Trading Symbol Avalo Therapeutics, Inc. [AVTX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector					
(Last) (First) (Middle) C/O AVALO THERAPEUTICS, INC., 540 GAITHER ROAD, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 03/31/2022							-	Officer (give	title below)	Oth	er (specify below	)
(Street) ROCKVILLE, MD 20850				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)			Т	able	I - Non-l	Deriva	ative Securitie	s Acquir	ed, Disposed	of, or Benef	ficially Owne	d	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	2A. Deeme Execution any (Month/Da		Date, if	3. Transaction Code (Instr. 8)		(A)	Securities Acqu ) or Disposed o str. 3, 4 and 5)					Ownership Form: I Direct (D) or Indirect (	7. Nature of Indirect Beneficial Ownership Instr. 4)	
							Co	ode V	Am	nount (A) or (D)	Price				(I) (Instr. 4)	
			Table II					in that a cu	nis fo irrent ispos	who respond orm are not re tly valid OME ed of, or Bene vertible securi	equired to control	o respond on number.			nys	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year) f tive	Execution Date, if	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Da		te	7. Title of Unde Securiti (Instr. 3	es		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivative Security: Direct (D) or Indirects (I)	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (Right to Buy)	\$ 0.7247	03/31/2022		A		30,359 (1)		03/31/2	2022	03/31/2032	Comm	130.339	\$ 0	30,359	D	

#### **Reporting Owners**

		Relationships					
	Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
5	XAPLAN GILLA C/O AVALO THERAPEUTICS, INC. 40 GAITHER ROAD, SUITE 400 ROCKVILLE, MD 20850	X					

#### **Signatures**

/s/ Jennifer Zoltoski, by Power of Attorney	04/04/2022		
**Signature of Reporting Person	Date		

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 100% of the stock option will immediately vest on the date that it is granted.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.